Quest Diagnostics Inc (DGX) KPIs and segments
Close on Nov 18, 2026Market cap $28.57BP/E 25.9Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Quest Diagnostics · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Quest Diagnostics: 40 chỉ số vận hành, trong đó có Test Requisitions Processed, Total Patient Access Points và Courier Vehicle Fleet, lấy từ 286 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DIS business($M) | 3,035 | 2,978 | 2,832 | 2,742 | 2,755 | 2,699 | 2,589 | 2,556 | 2,427 | 2,333 | 2,298 | 2,221 | |
All other operating segments($M) | 62 | 65 | 63 | 64 | 61 | 62 | 63 | 65 | 61 | 64 | 68 | 67 | |
DIS business($M) | 538 | 541 | 457 | 439 | 482 | 494 | 414 | 430 | 407 | 420 | 373 | 371 | |
All other operating segments($M) | 9 | 10 | 7 | 8 | 9 | 7 | 8 | 10 | 6 | 8 | 9 | 8 | |
General corporate activities($M) | -68 | -92 | -65 | -61 | -105 | -63 | -76 | -79 | -83 | -73 | -82 | -112 | |
Test Requisitions Processed3 | |||||||||||||
DIS Requisition Volume Growth (YoY)(%)3 | 14.5% | 13.1% | 10.9% | 8.5% | 12.5% | 16.3% | 12.4% | 13.9% | 5.5% | 1.1% | 1.6% | 1.9% | |
DIS Organic Requisition Volume Growth (YoY)(%) | 14.4% | 13.0% | 10.8% | 7.9% | 3.9% | 2.1% | -0.9% | 0.6% | 0.5% | 0.7% | 1.0% | 1.4% | |
DIS Underlying Volume Growth — Excl. Corewell & Fresenius Partnerships (YoY)(%) | 5.0% | 4.1% | 3.8% | 4.1% | |||||||||
Volume Growth Contribution from Corewell Health & Fresenius Partnerships(%) | 9.5% | 9.0% | 7.0% | ||||||||||
DIS Revenue per Requisition Change (YoY)(%)1 | -4.2% | -2.8% | -1.3% | -0.1% | 0.8% | -0.4% | 0.3% | 0.2% | 3.3% | 1.6% | 0.1% | -3.5% | |
DIS Underlying Revenue per Requisition Growth — Excl. Corewell & Fresenius Mix (YoY)(%) | 1.7% | 2.9% | 2.5% | 3.0% | |||||||||
Consolidated Net Revenue Growth (YoY)(%)3 | 10.0% | 10.2% | 9.2% | 7.1% | 13.1% | 15.2% | 12.1% | 14.5% | 8.5% | 2.5% | 1.5% | -1.9% | |
Consolidated Organic Net Revenue Growth (YoY)(%) | 10.0% | 10.0% | 9.0% | 6.4% | 6.8% | 5.2% | 2.4% | 4.8% | 4.2% | 1.8% | 0.8% | -2.7% | |
DIS Segment Revenue Growth (YoY)(%) | 10.2% | 10.3% | 9.4% | 7.3% | 13.5% | 15.7% | 12.7% | 15.1% | 9.0% | 2.8% | 1.7% | -2.0% | |
Diagnostic Solutions Revenue Growth (YoY)(%) | 2.3% | 4.3% | 0.8% | -0.9% | -1.0% | -3.1% | -7.7% | -3.5% | -7.9% | -8.8% | -5.0% | -0.7% | |
DIS Share of Consolidated Net Revenues(%)5 | 98.0% | 98.0% | 98.0% | 98.0% | 98.0% | 98.0% | 97.0% | 97.0% | 97.0% | ||||
Healthcare Insurers — Total Revenue Share(%)2 | 37.0% | 37.0% | 36.0% | 39.0% | 40.0% | 38.0% | 41.0% | 39.0% | 40.0% | ||||
Healthcare Insurers — Fee-for-Service Share(%) | 35.0% | 35.0% | 33.0% | 37.0% | 37.0% | 35.0% | 38.0% | 36.0% | 37.0% | ||||
Healthcare Insurers — Capitated Plans Share(%) | 2.0% | 2.0% | 3.0% | 2.0% | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% | ||||
Client Payers (Hospitals, Physicians, Employers & Other Labs) — Revenue Share(%) | 33.0% | 32.0% | 32.0% | 31.0% | 30.0% | 31.0% | 33.0% | 33.0% | 33.0% | ||||
Government Payers — Revenue Share(%) | 16.0% | 16.0% | 16.0% | 16.0% | 16.0% | 16.0% | 13.0% | 11.0% | 12.0% | ||||
Patients (Self-Pay, Deductibles, Coinsurances & QuestHealth.com) — Revenue Share(%) | 12.0% | 13.0% | 14.0% | 12.0% | 12.0% | 13.0% | 10.0% | 14.0% | 12.0% | ||||
Diagnostic Solutions — Revenue Share(%) | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 3.0% | 3.0% | 3.0% | ||||
Net Accounts Receivable Share — Healthcare Insurers(%)4 | 23.0% | 25.0% | 27.0% | 27.0% | 29.0% | 27.0% | 29.0% | 26.0% | 27.0% | 26.0% | 28.0% | 24.0% | |
Net Accounts Receivable Share — Client Payers(%) | 48.0% | 44.0% | 43.0% | 43.0% | 41.0% | 43.0% | 41.0% | 45.0% | 42.0% | 42.0% | 40.0% | 45.0% | |
Net Accounts Receivable Share — Government Payers(%) | 8.0% | 9.0% | 8.0% | 8.0% | 9.0% | 8.0% | 8.0% | 7.0% | 8.0% | 7.0% | 7.0% | 7.0% | |
Net Accounts Receivable Share — Patients(%) | 19.0% | 20.0% | 20.0% | 20.0% | 19.0% | 20.0% | 20.0% | 20.0% | 20.0% | 22.0% | 21.0% | 20.0% | |
Net Accounts Receivable Share — Diagnostic Solutions(%) | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 3.0% | 3.0% | 4.0% | 4.0% | |
Noncontrolling Interests in Consolidated Joint Ventures (Equity)($M)3 | 318 | 303 | 300 | 36 | 37 | 37 | 33 | 35 | 32 | 39 | 37 | 35 | |
Redeemable Noncontrolling Interest (Mezzanine Equity)($M) | 81 | 80 | 79 | 80 | 81 | 81 | 81 | 83 | 80 | 79 | 77 | 76 | |
Net Income Attributable to Noncontrolling Interests (Consolidated Hospital JVs)($M) | 14 | 14 | 12 | 11 | 14 | 14 | 15 | 14 | 11 | 11 | 14 | 13 | |
Equity in Earnings of Unconsolidated Joint Ventures, Net of Taxes($M) | 9 | 10 | 4 | 7 | 8 | 9 | 18 | 5 | 6 | 0 | 8 | 8 | |
Adjusted Operating Income (Non-GAAP)($M)3 | 517 | 502 | 447 | 429 | 458 | 466 | 406 | 409 | 385 | 398 | 349 | 338 | |
Adjusted Operating Income Margin(%) | 16.7% | 16.5% | 15.4% | 15.3% | 16.3% | 16.9% | 15.3% | 15.6% | 15.5% | 16.6% | 14.8% | 14.8% | |
Adjusted Net Income Attributable to Quest Diagnostics($M) | 338 | 350 | 281 | 273 | 296 | 298 | 251 | 253 | 262 | 266 | 230 | 245 | |
Adjusted Diluted Earnings per Share($) | 3 | 3.12 | 2.50 | 2.42 | 2.60 | 2.62 | 2.21 | 2.23 | 2.30 | 2.35 | 2.04 | 2.15 | |
Restructuring & Integration Charges in Operating Income($M)2 | 3 | 4 | 7 | 16 | 11 | 7 | 19 | 17 | 18 | 10 | 17 | 11 | |
Restructuring & Integration Charges — Cost of Services($M) | 1 | 1 | 1 | 4 | 1 | 1 | 6 | 8 | 5 | 1 | 13 | 4 | |
Restructuring & Integration Charges — SG&A($M) | 2 | 3 | 6 | 11 | 10 | 6 | 13 | 9 | 15 | 9 | 4 | 7 | |
Operating Lease Right-of-Use Assets($M)1 | 670 | 678 | 691 | 657 | 649 | 655 | 656 | 651 | 661 | 603 | 579 | 602 | |
ROU Assets Obtained in Exchange for New Operating Lease Liabilities($M) | 40 | 39 | 62 | 44 | 44 | 52 | 33 | 52 | 35 | ||||
Intangible Assets, Net($M) | 1,634 | 1,672 | 1,717 | 1,636 | 1,662 | 1,706 | 1,725 | 1,763 | 1,716 | 1,202 | 1,192 | 1,166 | |
Monthly Common Shares Repurchased1 | |||||||||||||
Remaining Share Repurchase Authorization($M) | 1,200 | 1,300 | 1,400 | 400 | 700 | 900 | 900 | 900 | 1,000 | 1,000 | 1,000 | 1,000 | |
U.S. Census QSS Industry Revenue — Medical & Diagnostic Laboratories (NAICS 6215)($M)1 | 20,528 | 19,569 | 19,997 | 19,677 | 19,718 | 18,722 | 19,104 | 18,893 | 18,483 | 17,963 | 17,943 | ||
U.S. Census QSS Industry Revenue — Ambulatory Health Care Services (NAICS 621)($M) | 414,886 | 395,174 | 407,176 | 398,164 | 389,960 | 373,423 | 380,950 | 366,854 | 362,208 | 347,178 | 347,128 | ||
U.S. BEA Personal Consumption Expenditures — Health Care Services ($B SAAR)1 | 3,859 | 3,790 | 3,700 | 3,667 | 3,615 | 3,530 | 3,465 | 3,418 | 3,358 | 3,288 | 3,244 | 3,159 | |
U.S. BEA Real PCE Quantity Index — Health Care Services (2017 = 100)(×) | 137.52 | 135.90 | 133.62 | 133.63 | 132.73 | 130.45 | 129.02 | 127.88 | 126.71 | 124.83 | 123.75 | 121.53 | |
Labcorp Holdings (LH) — Consolidated Revenue($M)1 | 3,810 | 3,731 | 3,538 | 3,516 | 3,564 | 3,527 | 3,345 | 3,329 | 3,282 | 3,221 | 3,177 | 3,033 | |
Labcorp Holdings (LH) — Operating Income($M) | 402 | 452 | 381 | 268 | 397 | 394 | 326 | 216 | 254 | 295 | 321 | -123 | |
Natera (NTRA) — Consolidated Revenue($M)1 | 794 | 753 | 697 | 665 | 592 | 547 | 502 | 476 | 440 | 413 | 368 | 311 | |
Natera (NTRA) — Operating Income (Loss)($M) | -68 | -76 | -94 | -23 | -98 | -110 | -79 | -65 | -39 | -44 | -74 | -85 | |
Guardant Health (GH) — Consolidated Revenue($M)1 | 361 | 335 | 302 | 281 | 265 | 232 | 203 | 202 | 191 | 177 | 168 | 155 | |
Guardant Health (GH) — Operating Loss($M) | -133 | -129 | -121 | -121 | -99 | -106 | -111 | -126 | -117 | -101 | -100 | -198 | |
DIS Segment — Net Revenues($M)2 | 3,035 | 2,978 | 2,832 | 2,742 | 2,755 | 2,699 | 2,589 | 2,556 | 2,427 | 2,333 | 2,298 | 2,221 | |
DIS Segment — Direct Operating Costs (Other Segment Items)($M) | 2,497 | 2,437 | 2,375 | 2,303 | 2,273 | 2,205 | 2,175 | 2,126 | 2,020 | 1,913 | 1,925 | ||
DIS Segment — Depreciation & Amortization($M) | 106 | 105 | 106 | 104 | 99 | 100 | 97 | 94 | 90 | 84 | 84 | ||
Diagnostic Solutions (All Other Segments) — Net Revenues($M)1 | 62 | 65 | 63 | 64 | 61 | 62 | 63 | 65 | 61 | 64 | 68 | 67 | |
Diagnostic Solutions — Depreciation & Amortization($M) | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | ||
General Corporate Unallocated Operating Expense($M)1 | -68 | -92 | -65 | -61 | -105 | -63 | -76 | -79 | -83 | -73 | -82 | -112 | |
General Corporate — Depreciation & Amortization($M) | 38 | 38 | 38 | 37 | 40 | 40 | 39 | 37 | 32 | 30 | 29 | ||
Consolidated Net Revenues (GAAP)($M)5 | 3,097 | 3,043 | 2,895 | 2,806 | 2,816 | 2,761 | 2,652 | 2,621 | 2,488 | 2,397 | 2,366 | 2,288 | |
Cost of Services (GAAP)($M) | 2,055 | 2,016 | 1,953 | 1,896 | 1,867 | 1,818 | 1,789 | 1,763 | 1,677 | 1,593 | 1,595 | 1,552 | |
Selling, General & Administrative Expenses (GAAP)($M) | 523 | 529 | 504 | 504 | 501 | 486 | 476 | 466 | 448 | 416 | 440 | 407 | |
Consolidated Operating Income (GAAP)($M) | 479 | 459 | 399 | 386 | 386 | 438 | 346 | 361 | 330 | 355 | 300 | 267 | |
Net Income Attributable to Quest Diagnostics (GAAP)($M) | 312 | 320 | 252 | 245 | 245 | 282 | 220 | 222 | 226 | 229 | 194 | 192 | |
Diluted Earnings per Share (GAAP)($) | 2.78 | 2.84 | 2.24 | 2.16 | 2.47 | 1.94 | 1.99 | 2.03 | 1.72 | ||||
Operating Cash Flow($M)4 | 611 | 597 | 278 | 465 | 563 | 544 | 314 | 464 | 356 | 360 | 154 | 527 | |
Consolidated Depreciation & Amortization($M) | 147 | 146 | 147 | 145 | 142 | 143 | 140 | 135 | 125 | 117 | 116 | 109 | |
Capital Expenditures($M) | 166 | 138 | 114 | 158 | 144 | 108 | 117 | 123 | 106 | 92 | 104 | 72 | |
Cash Paid for Business Acquisitions, Net($M) | 1 | 0 | 38 | 50 | 34 | 17 | 0 | 383 | 1,533 | 106 | 142 | 0 | |
Cash Dividends Paid($M) | 95 | 96 | 88 | 90 | 89 | 90 | 84 | 84 | 84 | 84 | 79 | 80 | |
Total Assets($M)4 | 17,221 | 16,939 | 16,673 | 16,225 | 16,197 | 15,969 | 15,797 | 16,153 | 16,095 | 13,881 | 13,954 | 14,022 | |
Cash & Cash Equivalents($M) | 797 | 626 | 393 | 420 | 432 | 319 | 188 | 549 | 764 | 271 | 474 | 686 | |
Accounts Receivable, Net($M) | 1,712 | 1,666 | 1,587 | 1,408 | 1,456 | 1,419 | 1,404 | 1,304 | 1,376 | 1,319 | 1,322 | 1,210 | |
Goodwill($M) | 9,112 | 9,112 | 9,120 | 8,945 | 8,901 | 8,883 | 8,849 | 8,856 | 8,605 | 7,885 | 7,830 | 7,733 | |
Total Stockholders' Equity($M) | 7,950 | 7,819 | 7,666 | 7,206 | 7,295 | 7,265 | 6,962 | 6,813 | 6,841 | 6,656 | 6,469 | 6,342 | |
8 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Quest Diagnostics Incorporated (NYSE: DGX, CIK 0001022079) operates on a calendar fiscal year ending December 31 (latest annual filing: FY2025 ended December 31, 2025; latest quarterly filing: Q3 2026 ended September 30, 2026).
- Operating segments comprise Diagnostic Information Services (DIS — ~98% of consolidated net revenues across physician, hospital, and consumer clinical testing in the United States and Canada) and Diagnostic Solutions (DS — ~2% of net revenues across life-insurer risk assessment and healthcare IT).
- Strategic M&A and joint venture milestones reflected in operational series: (1) LifeLabs Inc. (Canada's largest community laboratory network) was acquired on August 23, 2024 for CAD $1.35B (~USD $1.0B), expanding PSCs from ~2,000 to ~2,400 and increasing government payer revenue share from 13% to 16%; and (2) the 51%-owned Diagnostic Lab of Michigan joint venture with Corewell Health closed in January 2026 and is consolidated in Quest Diagnostics' financial statements (driving Noncontrolling Interests equity from $36M at Q4 2025 to $318M at Q3 2026 and contributing 9.5 percentage points to Q3 2026 DIS requisition volume growth alongside the Fresenius Medical Care dialysis testing partnership).
- Quest Diagnostics prepares consolidated financial statements under U.S. GAAP and does not publish parent-only operating financial statements, so no consolidated-minus-standalone calculation applies. All cell values are strictly as published except standard period splits (Q4 = full year minus nine months; quarterly cash flows = year-to-date minus prior year-to-date), shown in italics with their exact formula.
Không hiện vì thiếu các kỳ gần đây (21)
- Daily Logistics Stops (>83,000 stops daily in FY2024–FY2025; >73,000 in FY2023) — disclosed only as lower-bound inequalities ('>').
- Clinical Laboratory Results Database Patient Data Points (>80 billion in FY2024–FY2025; >70 billion in FY2023; >60 billion in FY2021–FY2022) — disclosed only as lower-bound inequalities ('>').
- U.S. Insured Lives Health Plan Access (>90% of U.S. insured lives) — disclosed only as a lower-bound inequality ('over 90%').
- Electronic Health Record (EHR) Systems Interfaced (>1,000 EHR systems in FY2024–FY2025; >920 in FY2023) — disclosed only as lower-bound inequalities ('over' / '>').
- Total Global Headcount Including Part-Time & On-Call ('nearly 57,000' in FY2025 vs. 'approximately 56,000' in FY2024) — FY2025 disclosed only as an upper-bound approximation ('nearly'); Full-Time Employees (46,000 in FY2025) is included instead.
- QuestHealth.com Consumer Test Menu Size (>150 tests in FY2025) & Fresenius Dialysis Patients Served (>200,000 patients) — disclosed only as lower-bound inequalities ('over' / 'more than').
- Pending Patents Worldwide ('approximately 400' in FY2025 vs. 'nearly 400' in FY2024 and 'over 400' in FY2023) — only one non-bound annual period (FY2025).
- Hospital Reference Testing Revenue (~$1.2B in FY2025 vs. 'over $1 billion' in FY2023–FY2024) — only one non-bound annual period (FY2025).
- Advanced Diagnostics Five Clinical Areas Revenue (>$1.0B in FY2025) & Consumer Channel Revenue ('nearly $250M' in FY2025) — bound disclosures in a single fiscal year.
- LifeLabs Standalone Test Volume (~140M laboratory tests in FY2024 vs. ~23M test requisitions in FY2025) — unit definition changed from individual tests to requisitions across the two post-acquisition years (1 period per unit).
- LifeLabs Standalone Collection Centers (>350 centers in Canada) — disclosed only as a lower-bound inequality ('over 350').
- LifeLabs Standalone FY2025 GHG & Waste Disaggregation (Scope 1: 8,646 MT CO2e; Scope 2: 1,399 MT CO2e; Scope 3: 5,383 MT CO2e) — single annual period (first full year consolidated in the 2025 CR Report).
- SASB Total Energy Consumed (1,480,224 GJ in FY2025; 2,476,076 GJ in FY2021) & Total Medical Waste Tons (15,454 tons in FY2025; 10,860 MT in FY2021) — omitted from 2022–2024 CR Reports (gapped series).
- EEO-1 U.S. Headcount & Management Race/Gender Breakdowns (46,793 at FY2023; 43,144 at FY2024) — omitted from the 2025 Corporate Responsibility Report (lacks FY2025).
- Legacy Dollar Product Revenue Disaggregation (Routine Clinical Testing, COVID-19 Testing, Gene-Based & Esoteric, Anatomic Pathology in $M) — discontinued after Q3 2022 when Quest switched to percentage-of-revenue disaggregation.
- DIS Organic Revenue per Requisition Growth Excl. Acquisitions (FY2024Q4–FY2025Q3: +3.3%, +3.6%, +3.3%, +3.0%) — reported during the 12-month LifeLabs M&A window and replaced by ex-partnership Rev/Req disclosures from Q4 2025 onward.
- Monthly Average Price Paid per Repurchased Share — undefined in months with zero share repurchases (e.g., Jul–Aug 2026).
- Investor Day 2025 Market Sizing Estimates ($89B U.S. lab market, $5B Canadian lab market) & FY2026 Financial Guidance Ranges ($11.70B–$11.82B revenue, $1.75B OCF, $550M CapEx) — static industry estimates and forward guidance rather than historical operating actuals.
- ClinicalTrials.gov Study Counts (69 registered studies) & openFDA 510(k) Clearances (31 clearances through 2020) — registry counts rather than published periodic operating series (most new Quest assays launch as CLIA-validated Laboratory Developed Tests).
- Peer XBRL Series for Exact Sciences (EXAS, stopped at Q4 2025), Myriad Genetics (MYGN, latest Q2 2026), and NeoGenomics Revenue (NEO, concept tag break) — excluded due to incomplete coverage through Q3 2026.
- Derived Financial Subtotals (Gross Profit, EBITDA, Free Cash Flow) — Quest Diagnostics' GAAP financial statements do not publish these subtotals directly, and computed cross-line-item differences/sums are excluded.
Dữ liệu cập nhật 2026-11-06.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Diagnostic Information Services — Volume, Pricing & Physical Network
Revenue & Receivables Mix by Payer, Channel & Service Category
LifeLabs (Canada Subsidiary) & Consolidated Hospital Joint Ventures
Adjusted Profitability, Lab Infrastructure & Monthly Share Repurchases
Workforce, Workplace Safety & Environmental Sustainability
- Full-Time Employees5 kỳ
- Total Recordable Incident Rate (TRIR) — Direct Employees (×)5 kỳ
- Voluntary Turnover Rate — Non-Physician Employees (%)5 kỳ
- Scope 1 Direct GHG Emissions (Metric Tons CO2e)5 kỳ
- Scope 2 Indirect GHG Emissions — Location-Based (MT CO2e)5 kỳ
- Scope 3 Value-Chain GHG Emissions (MT CO2e)5 kỳ
- GHG Emissions Intensity — Scope 1 (MT CO2e per 1M Requisitions) (×)5 kỳ
- Biohazardous Waste Intensity (Metric Tons per 1M Requisitions) (×)4 kỳ
U.S. Clinical Laboratory Macro & Peer Benchmarks
- U.S. BLS Producer Price Index — Medical Laboratories (NAICS 621511) (×)105 kỳ
- U.S. BLS Consumer Price Index — Medical Care Services (×)104 kỳ
- U.S. BLS Employment — Ambulatory Health Care Services (Thousands)105 kỳ
- U.S. Census QSS Industry Revenue — Medical & Diagnostic Laboratories (NAICS 6215) ($M)34 kỳ
- U.S. BEA Personal Consumption Expenditures — Health Care Services ($B SAAR)35 kỳ
- Labcorp Holdings (LH) — Consolidated Revenue ($M)35 kỳ
- Natera (NTRA) — Consolidated Revenue ($M)35 kỳ
- Guardant Health (GH) — Consolidated Revenue ($M)35 kỳ
Operating Segments & Consolidated Financial Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Quest Diagnostics
- Quest Diagnostics Q3 2026 Form 10-Q (filed 2026-10-23) ↗
- Quest Diagnostics Form 10-K (FY2025) ↗
- Quest Diagnostics 2025 Corporate Responsibility Report ↗
- Quest Diagnostics Form 10-K (filed 2026-02-26) ↗
- Quest Diagnostics FY2025 Form 10-K (filed 2026-02-26) ↗
- Quest Diagnostics Form 10-Q (filed 2026-10-23) ↗
- Quest Diagnostics Form 8-K Earnings Release (filed 2026-10-22) ↗
- Quest Diagnostics Form 8-K Earnings Release (filed 2026-02-10) ↗
- U.S. Bureau of Labor Statistics / FRED (PCU621511621511) ↗
- U.S. Bureau of Labor Statistics / FRED (CUSR0000SAM2) ↗
- U.S. Bureau of Labor Statistics / FRED (CES6562100001) ↗
- U.S. Census Bureau Quarterly Services Survey / FRED (REV6215TAXABL144QNSA) ↗
See a number that looks wrong?